By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

REUTERS/Chris J. Ratcliffe/File Photo GSK is banking on new drugs in its infectious diseases portfolio, including its ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Pfizer (NYSE:PFE) and GSK (NYSE:GSK) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, ...

Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing ...

GSK) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, Abrysvo for respiratory syncytial virus (RSV) allegedly violated the British pharma giant’s patent rights ...

GSK said in the lawsuit that Pfizer began working on its RSV program around 2013, at least seven years after GSK began developing its shot. Pfizer denied the allegations and argued GSK's patents ...